Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Effect of Insulin Sensitizer Therapy on Atherothrombotic and Inflammatory Profiles Associated With Insulin Resistance

7 octobre 2013 mis à jour par: K. Sreekumaran Nair, Mayo Clinic
The objective of this study is to determine whether targeted pharmacological improvement of insulin sensitivity will normalize the associated elevations of thrombotic and inflammatory cardiovascular disease (CVD) biomarkers in individuals with insulin resistance.

Aperçu de l'étude

Description détaillée

Individuals with diabetes mellitus (DM) are disproportionately affected by atherothrombotic disorders, including cardiovascular, cerebrovascular, and peripheral vascular diseases. Atherothrombotic disease risk and mortality are also increased with metabolic syndrome, a constellation of risk factors present in more than 34% of adults, even in absence of diabetes. Yet, large clinical trials of diabetes therapies have shown that conventional cardiovascular disease (CVD) risk factors, specifically hyperglycemia and hypertension, do not fully account for increased CVD risk associated with DM.

There may be an etiologic link among insulin resistance, inflammation and thrombotic events. This study seeks to determine if certain two diabetes medications (the insulin sensitizing medications) will affect certain biomarkers (or laboratory tests) for CVD in individuals with untreated DM or impaired fasting glucose.

Patients will be screened for inclusion into this this double-blinded, randomized), placebo-controlled study. If inclusion criteria are met and exclusion criteria not met, patients will be enrolled in the the study. Half of the subjects will be randomized (like the flip of a coin) to take two insulin sensitizing, anti-diabetic drugs pioglitazone (Actos) and metformin (Glucophage) taken together for three months and the other half of the subjects will take corresponding placebo (dummy) tablets.

Laboratory measurements will be obtained on the morning(s) following the two in-patient overnight stays in the Mayo Clinic Clinical Research Unit. The first stay will be at baseline and the second stay will be 3 months after baseline. Insulin sensitivity will be measured in the morning following a standardized meal the preceding night, and after an overnight fast.

The changes (from baseline to 3 months) in insulin sensitivity, glycemic control, the lipid profile, thrombotic markers and inflammatory markers will be determined and compared between the two arms of the study (placebo versus insulin sensitizing drugs).

Type d'étude

Interventionnel

Inscription (Réel)

28

Phase

  • Phase 2

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

    • Minnesota
      • Rochester, Minnesota, États-Unis, 55905
        • Mayo Clinic

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

20 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion criteria:

  • We will study 30 patients with Type 2 Diabetes or impaired fasting glucose (15 men & 15 women) who are > 20 years old.
  • Only patients who use lifestyle modification to manage their diabetes and are not on any oral hypoglycemic agents or insulin will be included.
  • We will enroll subjects who have fasting glucose concentration greater than 100 mg/dl on two consecutive occasions and have a Body Mass Index between 27-36 kg/m^2.

Exclusion Criteria:

  • We will exclude patients whose blood glucose is above 180 mg/dl. This will avoid the need to perform home glucose monitoring and the potential of unblinding the study by the volunteers.
  • Patients taking oral hypoglycemic agents or insulin would be excluded.
  • Any diseases such as active cardiovascular disease, liver diseases, kidney failure (males with serum creatinine >= 1.5mg/dl, females >=1.4 mg/dl), active endocrinopathies, debilitating chronic disease, anemia, symptoms of undiagnosed illness, history of alcoholism (alcohol use > 4oz/day) or substance abuse, chronic neurological diseases including Alzheimer's disease, stroke, etc, myopathies or any other active disease that may potentially affect the outcome measures.
  • Patients on medicines such as beta blockers, corticosteroids, tricyclics, benzodiazepines, opiates, barbiturates, anticoagulants and any other drugs or preparations that may affect mitochondrial function will be excluded.
  • People allergic to any of the class of drug such as lidocaine will also be excluded.
  • People with pacemakers, certain aneurysm clips and claustrophobia will also be excluded as they cannot undergo magnetic resonance imaging.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Double

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Comparateur actif: Insulin Sensitizer Therapy
Two insulin sensitizing drugs will be taken together for 3 months; metformin 1000 mg twice daily plus pioglitazone 45 mg daily.
To minimize side effects the metformin will be initiated at 500 mg twice daily with meals and increased to 1 gm twice daily with meals after two weeks and continue to a total of 3 months of dosing.
Autres noms:
  • Glucophage
  • Glumetza
  • Fortamet
  • Riomet
  • Glucophage Extended Release (XR)
To minimize side effects, the pioglitazone will be initiated at 30 mg daily and increased to 45 mg daily after two weeks, and continue to a total of 3 months of dosing.
Autres noms:
  • Actos
Comparateur placebo: Placebo
Placebo tablets were used to match the active comparator drugs and dosing regimen.
Placebo tablets matching the metformin and pioglitazone tablets are given in the same regimen as the active drug arm for 3 months.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Change From Baseline in Insulin Sensitivity as Measured by Glucose Infusion Rate (GIR)
Délai: Baseline, 3 months
Insulin sensitivity was measured the morning after an overnight fast during an in-patient stay in the Clinical Research Unit & was determined by the mean GIR necessary to maintain euglycemia during a hyperinsulinemic (1.5 mcIU/kg of FFM per minute)-euglycemic (85-95 mg/dL) clamp. The clamp is an 8 hour process where a hand vein is catheterized to collect blood samples and intravenous lines are used to infuse glucose, saline, insulin, phenylalanine and amino acid solutions at at pre-specified times/rates. The mean GIR was calculated as the rate per kilograms of fat-free mass (FFM) during 4 hours of steady-state (hours 4-8 of the 8 hour clamp) reported as micromols/kilogram of FFM per minute. The FFM was measured by dual-energy x-ray absorptiometry (DEXA) scan. Insulin was infused with 5% essential amino acid solution (3mL/kg of FFM/hour) to prevent the insulin-dependent decrease of amino acids during insulin infusion.
Baseline, 3 months

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Change From Baseline in Fasting Blood Glucose Level
Délai: Baseline, 3 months
Glucose (sugar) was measured in the blood and reported in milligrams per deciliter (mg/dL).
Baseline, 3 months
Change From Baseline in Glycosylated Hemoglobin (HbA1c)
Délai: Baseline, 3 months
HbA1c is a measure of average blood sugar levels over the preceding 3 month period. HbA1c was measured by ion-exchange chromatography and reported as a percentage.
Baseline, 3 months
Change From Baseline in Insulin Levels
Délai: Baseline, 3 months
Insulin levels in the blood were measured by immunoenzymatic assay and reported in micro International Units per milliliter (mcIU/mL).
Baseline, 3 months
Change From Baseline in Lipid Profile
Délai: Baseline, 3 months
Change in lipids were measured by the change from baseline to 3 months of triglycerides, high-density lipoprotein cholesterol (HDL-C) and non-high-density lipoprotein cholesterol (non-HDL-C). All were reported in milligrams/deciliter (mg/dL).
Baseline, 3 months
Change From Baseline in the Thrombotic Biomarker Fibrinogen
Délai: Baseline, 3 months
Fibrinogen was measured by thrombin clotting rate assay (Beckman Coulter, Inc. Brea, California) and reported in milligrams/deciliter (mg/dL).
Baseline, 3 months
Change From Baseline in the Thrombotic Biomarker Plasminogen Activator Inhibitor-1 (PAI-1)
Délai: Baseline, 3 months
PAI-1 was measured by enzyme-linked immunosorbent assay (Diagnostica Stago Inc., Parsippany, New Jersey) and reported in nanograms per milliliter (ng/mL).
Baseline, 3 months
Change From Baseline in the Inflammatory Biomarker Interleukin 6 (IL-6)
Délai: Baseline, 3 months
IL-6 is an inflammatory cytokine and reported in picograms per deciliter (pg/dL).
Baseline, 3 months
Change From Baseline in the Inflammatory Biomarker C-Reactive Protein (CRP)
Délai: Baseline, 3 months
CRP is an inflammatory cytokine and is reported in milligrams per deciliter (mg/dL).
Baseline, 3 months
Change From Baseline in Inflammatory Biomarker Tumor Necrosis Factor-alpha (TNF-α)
Délai: Baseline, 3 month
TNF-α is an inflammatory cytokine and is reported in picograms/milliliter (pg/mL).
Baseline, 3 month
Change From Baseline in the Inflammatory Biomarker Adiponectin
Délai: Baseline, 3 months
Adiponectin is an anti-inflammatory cytokine and is reported in milligrams per milliliter (mg/mL).
Baseline, 3 months

Autres mesures de résultats

Mesure des résultats
Description de la mesure
Délai
Change From Baseline in Body Mass Index
Délai: Baseline, 3 months
Body Mass Index (BMI) is a health index for comparing weight to height. BMI is a person's weight in kilograms (kg) divided by his or her height in meters squared. The body mass index is an indication if a person is at a suitable weight for his height on an approximation of body fat.
Baseline, 3 months
Change From Baseline in Body Fat
Délai: Baseline, 3 months
Body fat is reported as a percentage of body weight.
Baseline, 3 months
Change From Baseline in Fat-Free Mass (FFM)
Délai: Baseline, 3 months
FFM was measured using dual energy x-ray absorptiometry (DEXA) scans and is reported in kilograms (kg).
Baseline, 3 months

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude

1 août 2005

Achèvement primaire (Réel)

1 août 2010

Achèvement de l'étude (Réel)

1 août 2010

Dates d'inscription aux études

Première soumission

26 février 2007

Première soumission répondant aux critères de contrôle qualité

5 mars 2007

Première publication (Estimation)

6 mars 2007

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Estimation)

31 octobre 2013

Dernière mise à jour soumise répondant aux critères de contrôle qualité

7 octobre 2013

Dernière vérification

1 octobre 2013

Plus d'information

Termes liés à cette étude

Autres numéros d'identification d'étude

  • 05-004002
  • UL1RR024150 (Subvention/contrat des NIH des États-Unis)
  • KL2RR024151 (Subvention/contrat des NIH des États-Unis)
  • R01DK041973 (Subvention/contrat des NIH des États-Unis)

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner